<DOC>
	<DOCNO>NCT02491905</DOCNO>
	<brief_summary>This study evaluate safety efficacy HL tablet reduce hepatic fat non-alcoholic fatty liver disease patient . The patient allocate three group ; low dose , high dose , placebo control group .</brief_summary>
	<brief_title>Safety Efficacy HL Tablet Non-alcoholic Fatty Liver Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Age 19 75 2 . Nonalcoholic fatty liver disease patient Diagnosed abdomen ultrasonic examination Nondrinker ( alcohol intake per week : femaleunder 140g , maleunder 210g ) 3 . ALT AST high normal range ( 4 time normal range ) 4 . Voluntary agreement enrollment 1 . The ratio AST/ALT 2 2 . Type I diabetes mellitus patient 3 . Any dysfunction liver besides nonalcoholic fatty liver disease 4 . Alcoholic fatty liver disease patient heavy drinker 5 . Prior treatment medicine affect treatment nonalcoholic fatty liver disease within 3 month 6 . Patient take product affect BMI hyperlipidemia 7 . Any dyscrasia investigator considers appropriate study 8 . Bariatric surgery within 6 month 9 . Any disease able change distribution cytokine 10 . Any treatment affect liver function within 1 month 11 . Participation clinical trial within 3 month 12 . Person use MRS 13 . Pregnancy breastfeed 14 . Fertile woman use contraception 15 . Sensitive investigational product 16 . Any condition investigator considers appropriate study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>